Presidio Ospedaliero Garibaldi-Nesima

Catania 95122

1 studies enrolling now · 7 studies all time

What they study most

First Line Non-Small Cell Lung Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Metastatic Cholangiocarcinoma, SARS-CoV2 Infection, Ulcerative Colitis, Unresectable Cholangiocarcinoma, Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

Studies at this site

• Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer — Recruiting now
• ABTECT - Maintenance — Running, not enrolling
• ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 — Completed
• A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma — Stopped early
• Avelumab in First-line NSCLC (JAVELIN Lung 100) — Completed
• Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) — Completed
• Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) — APPROVED_FOR_MARKETING